Fitbit's new enterprise offering "Ready for Work" uses symptom checker app and vital signs data to recommend whether an employee can work

June 17, 2020
CPG More...
“Better-for-You” Transformation More...
by Danielle Bradnan
Very important

The vital signs monitoring is of particular interest because early evidence suggests that heart rate variability and sleep may indicate an oncoming immune response due to a viral pathogen. However, the research to determine the link between vital signs and COVID-19 has only been going on since March (Fibit's study began in May). Any digital biomarkers used to make recommendations either are from an earlier study based on the flu or are extremely preliminary data, without the scientific review necessary to make recommendations yet. Clients should monitor this development with interest because it represents the first commercialized digital biomarker offering for consumers, but be aware that it is based on early-stage research.

For the original news article, click here .

Further Reading

Recovering COVID-19 patients may face higher risk of developing blood clots

News Commentary | April 14, 2021

Scientists at Singapore's Nanyang Technological University reported that recovering COVID‑19 patients with preexisting cardiovascular conditions may be at a higher risk of developing blood clots. The findings come at a time when vaccines from AstraZeneca and Johnson & Johnson have reported rare ... Not part of subscription

InteliCare receives $70,000 grant to build machine learning-based health prediction software for the elderly

News Commentary | June 10, 2021

In partnership with Macquarie University and the University of Sydney, InteliCare is aiming to create a product that can predict healthcare outcomes around elderly patients. The idea behind the system is to be able to predict aging concerns like chronic disease, falls, and dementia in time to alert ... Not part of subscription

Royal Philips begins clinical trials for first at-home ECG solution

News Commentary | February 07, 2022

Philips' device will be the industry's first attempt at an at‑home, 12‑lead ECG (electrocardiogram). It will include access to Philips' cardiac monitoring portfolio, which pairs cloud‑based data collection with data readings it claims are comparable to clinical ECGs. While the solution is still in ... Not part of subscription